Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is positioned favorably due to its ongoing development of stenoparib, which has demonstrated promising clinical benefits, including a median overall survival exceeding 25 months for patients in its Phase 2 trial. The company’s proprietary Drug Response Predictor (DRP) technology is enhancing patient selection and clinical outcomes, thereby strengthening its market potential in the oncology sector. Additionally, the current valuation reflects a significant upside, supported by a net present value (NPV) analysis that indicates an attractive investment opportunity, even while acknowledging the associated high risks.

Bears say

Allarity Therapeutics Inc reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which was slightly better than estimates but still indicative of ongoing financial challenges. The company also faced similar losses of $2.37 million in previous quarters, further underscoring a consistent pattern of negative earnings performance. Compounding these financial setbacks are significant risks including liquidity challenges, regulatory hurdles, and competitive pressures, which contribute to a negative outlook for the company's stock.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.